The Institute of Medicine's recommendations that HHS consider cost and affordability in determining which benefits insurers participating in exchanges must cover will ensure flexibility and have opened "a long-overdue debate between employers and some powerful special interests that benefit from costly new mandates," Pharmaceutical Care Management Association President and CEO Mark Merritt says.

New PCMA Ad: Small Businesses Oppose Costly Mandates Pushed by Drugstore, Drug Company Lobbies

Full Story:
BNA (free content)

Related Summaries